Novomix 50 Flexpen (Insulin Aspart)

Insulin aspart, the active ingredient in Novomix 50 Flexpen, is an insulin analog presented as a rapid‑acting formulation for subcutaneous injection use. It lowers blood glucose in people with diabetes mellitus. GNH USA supplies Novomix 50 Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Novomix 50 Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novomix 50 Flexpen is an insulin analog that acts on the glucose regulation pathway in diabetes management. - Type 1 diabetes mellitus: improves basal and prandial glycaemic control. - Type 2 diabetes mellitus: provides mealtime insulin coverage alongside basal insulin. - Gestational diabetes mellitus: assists in achieving target blood glucose levels when diet and oral agents are insufficient.

Novomix 50 Flexpen may cause a range of adverse reactions.

Common Side Effects: - Hypoglycaemia: low blood glucose levels. - Injection site reactions: redness, swelling or itching. - Lipodystrophy: localized fat tissue changes. - Weight gain: increase in body weight. - Edema: mild fluid retention.

Serious or Rare Side Effects: - Severe hypoglycaemia with neurological impairment. - Anaphylactic reaction: hives, swelling, airway compromise. - Stevens‑Stevenson Syndrome. - Acute pancreatitis. - Hypersensitivity vasculitis. - Persistent hyperglycaemia despite therapy.

When administering Novomix 50 Flexpen, consider the following safety measures: - Monitor: regular blood glucose monitoring is essential. - Adjust: insulin doses may need adjustment during illness, stress, or changes in diet. - Educate: patients should be trained to recognize the signs of hypoglycaemia.\nStore at 2-8°C: ​       t    t \